304 related articles for article (PubMed ID: 15048791)
1. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
[TBL] [Abstract][Full Text] [Related]
3. Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.
Parant F; Rivet C; Boulieu R; Gagnieu MC; Dumortier J; Boillot O; Lachaux A
Ther Drug Monit; 2009 Dec; 31(6):727-33. PubMed ID: 19881404
[TBL] [Abstract][Full Text] [Related]
4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
5. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
6. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
[TBL] [Abstract][Full Text] [Related]
10. Significance of mycophenolate monitoring in liver transplant recipients: toward the cut-off level.
Sarvary E; Nemes B; Varga M; Gaal I; Monostory K; Langer RM; Gorog D; Fazakas J; Kobori L; Fehervari I; Gerlei Z
Transplant Proc; 2012 Sep; 44(7):2157-61. PubMed ID: 22974941
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
Weber LT; Shipkova M; Armstrong VW; Wagner N; Schütz E; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B
Clin Chem; 2002 Mar; 48(3):517-25. PubMed ID: 11861442
[TBL] [Abstract][Full Text] [Related]
12. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
13. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
[TBL] [Abstract][Full Text] [Related]
14. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
[TBL] [Abstract][Full Text] [Related]
16. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
[TBL] [Abstract][Full Text] [Related]
17. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation.
Borrows R; Chusney G; Loucaidou M; James A; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
Ther Drug Monit; 2007 Feb; 29(1):122-6. PubMed ID: 17304160
[TBL] [Abstract][Full Text] [Related]
18. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
Filler G; Foster J; Berard R; Mai I; Lepage N
Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
[TBL] [Abstract][Full Text] [Related]
19. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
Kiberd BA; Lawen J; Daley C
Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
Trkulja V; Lalić Z; Nađ-Škegro S; Lebo A; Granić P; Lovrić M; Pasini J; Božina N
Ther Drug Monit; 2014 Aug; 36(4):456-64. PubMed ID: 24518562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
